Bifogade filer
Q-linea participates in comparative rapid AST study
Kurs
-4,55%
Likviditet
0,47 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-10-30 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-07-10 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-28 | N/A | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2026-05-27 | N/A | Årsstämma |
| 2026-04-30 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-04 | - | Bokslutskommuniké 2025 |
| 2025-10-21 | - | Extra Bolagsstämma 2026 |
| 2025-10-20 | - | Kvartalsrapport 2025-Q3 |
| 2025-07-14 | - | Split QLINEA 1000:1 |
| 2025-07-10 | - | Kvartalsrapport 2025-Q2 |
| 2025-06-26 | - | Årsstämma |
| 2025-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2025-04-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-04-03 | - | Extra Bolagsstämma 2025 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-05 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-11 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Årsstämma |
| 2024-06-12 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-27 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-07-03 | - | Extra Bolagsstämma 2023 |
| 2023-06-13 | - | Årsstämma |
| 2023-05-24 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2021-05-25 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | X-dag ordinarie utdelning QLINEA 0.00 SEK |
| 2019-05-22 | - | Årsstämma |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that the company will participate in a study comparing the benefits of three different rapid AST devices to current standard of care.
A total of 240 patients treated for Gram-negative septicemia will be enrolled in the study at a major European hospital. Septicemia is a bacterial infection that spreads into the bloodstream and sepsis can be the body's response to that infection. Positive blood culture samples will be analyzed using three rapid phenotypic AST systems. Diagnostic performance, workflow adaptability, and reduction in time to optimal antibiotic treatment for the three systems will be compared to the current standard of care method.
“We are delighted to announce the participation of Q-linea in this comparative study. Considering the breadth of the ASTar G- antibiotic panel and the speed of results, we believe that patients will derive major clinical benefits from its utilization," says Jonas Jarvius, CEO of Q-linea.
For more information, please contact:
Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60
Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.